A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated CancersMoonSun Jung, Michelle J. Henderson, Amanda J. Russell et al.|Cancer Research|2016Cited by 137
The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugsPei Y. Liu, Tao Liu, Bernard Atmadibrata et al.|Oncotarget|2016Cited by 21